Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Research Report 2022: Focus on SX-PCK9, K-312, DCRPCSK-9, & LY3015014 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Proprotein Convertase Subtilisin/Kexin Type 9 Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2027” report has been added to ResearchAndMarkets.com’s offering.

The report predicts the global proprotein convertase subtilisin/kexin type 9 market to grow with a CAGR of 9% over the forecast period from 2021-2027.

The report on the global proprotein convertase subtilisin/kexin type 9 market provides qualitative and quantitative analysis for the period from 2019 to 2027. The study on proprotein convertase subtilisin/kexin type 9 market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2019 to 2027.

The report on proprotein convertase subtilisin/kexin type 9 market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global proprotein convertase subtilisin/kexin type 9 market over the period of 2019 to 2027. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter’s five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global proprotein convertase subtilisin/kexin type 9 market over the period of 2019 to 2027. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings

1) Drivers

• The increasing frequency of atherosclerotic cardiovascular diseases and familial hypercholesterolemia is expected to drive market growth in the upcoming years

2) Restraints

• The high cost of pcsk9 inhibitors is likely to hamper market growth

3) Opportunities

• Various technological advancements, such as the development of novel drug classes will create opportunities for the market to grow.

Company Profiles

• Pfizer Inc
• Novartis AG
• Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
• Ensemble Therapeutics Corp
• The Medicines Company
• Regeneron Pharmaceuticals In
• AFFiRiS AG
• BioLingus AG
• Catabasis Pharmaceuticals Inc
• Bioleaders Corp

Segment Covered

The Global Proprotein Convertase Subtilisin/kexin Type 9 Market by Product

• SX-PCK9
• K-312
• DCRPCSK-9
• LY3015014
• Others

The Global Proprotein Convertase Subtilisin/kexin Type 9 Market by Application

• Cardiovascular Disease
• Homozygous Familial Hypercholesterolemia
• Liver Disease
• Metabolic Syndrome
• Others

For more information about this report visit https://www.researchandmarkets.com/r/s4x1e6

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900